Status:

COMPLETED

Atomoxetine, Placebo and Parent Management Training in Autism

Lead Sponsor:

University of Rochester

Collaborating Sponsors:

University of Pittsburgh

Ohio State University

Conditions:

Autism

Pervasive Development Disorder

Eligibility:

All Genders

5-14 years

Phase:

PHASE4

Brief Summary

The study will evaluate the effectiveness of atomoxetine (Strattera) with and without Parent Management Training (PMT) in children with Autism, Asperger's Disorder, or Pervasive Developmental Disorder...

Eligibility Criteria

Inclusion

  • Children 5 yrs to 14 years 11 mos with clinical diagnosis of Autism, Asperger's Disorder, or PDDNOS based upon the ADI-R and clinical evaluation by DSM-IV criteria,
  • Mental age equal to or greater than 24 months,
  • ADHD symptoms based upon the CASI and clinical confirmed diagnosis,
  • CGIS-S rating of 4 or grater for ADHD symptoms,
  • A mean item score of \>1.5 on both the Parent and Teacher (non-parent caregiver) SNAP-IV 18 ADHD symptoms or the 9-symptom hyperactive-impulsive subscale (symptoms must be cross-situational),
  • Reliable care provider available to bring subject to clinic visits and weekly sessions.

Exclusion

  • DSM-IV diagnosis of schizophrenia, schizoaffective disorder psychotic disorder NOS,bipolar disorder, or major depression (if accompanied by a family history of bipolar disorder) based upon evidence of suicidality, CASI, and clinical interview/history,
  • Prior failed adequate trial of atomoxetine,
  • Use of other psychotropic medications that produce CNS effects,
  • Diagnosis of bipolar disorder, major depression, hypertension, cardiovascular disease, narrow angle glaucoma, other significant physical illness,
  • Pregnancy or sexually active females (intercourse in the past 6 months, reported by either the subject or caregiver),
  • Currently on effective medication treatment for ADHD,
  • Prior involvement in Parent Management Training or other similar program,
  • Currently on albuterol or taking beta blockers,
  • Taking supplements or other complementary medical treatments where dose cannot be held at current level for duration of study

Key Trial Info

Start Date :

October 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2014

Estimated Enrollment :

128 Patients enrolled

Trial Details

Trial ID

NCT00844753

Start Date

October 1 2008

End Date

April 1 2014

Last Update

February 4 2016

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

University of Rochester Medical Center

Rochester, New York, United States, 14642

2

Ohio State University

Columbus, Ohio, United States

3

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States